Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−22.9517 EUR
−20.78 M EUR
57.90 M EUR
4.66 M
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Cidara Therapeutics, Inc. stocks are traded under the ticker A3D4A6.
A3D4A6 stock hasn't changed in a week, the last month showed zero change in price, over the last year Cidara Therapeutics, Inc. has showed a 7.22% increase.
We've gathered analysts' opinions on Cidara Therapeutics, Inc. future price: according to them, A3D4A6 price has a max estimate of 43.52 EUR and a min estimate of 23.21 EUR. Watch A3D4A6 chart and read a more detailed Cidara Therapeutics, Inc. stock forecast: see what analysts think of Cidara Therapeutics, Inc. and suggest that you do with its stocks.
A3D4A6 stock is 7.22% volatile and has beta coefficient of 1.22. Track Cidara Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cidara Therapeutics, Inc. there?
Yes, you can track Cidara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cidara Therapeutics, Inc. is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
A3D4A6 earnings for the last quarter are −2.20 EUR per share, whereas the estimation was −3.82 EUR resulting in a 42.35% surprise. The estimated earnings for the next quarter are −3.38 EUR per share. See more details about Cidara Therapeutics, Inc. earnings.
Cidara Therapeutics, Inc. revenue for the last quarter amounts to 0.00 EUR, despite the estimated figure of 389.19 K EUR. In the next quarter, revenue is expected to reach 231.83 K EUR.
A3D4A6 net income for the last quarter is −14.36 M EUR, while the quarter before that showed −83.47 M EUR of net income which accounts for 82.80% change. Track more Cidara Therapeutics, Inc. financial stats to get the full picture.
No, A3D4A6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2025, the company has 69.00 employees. See our rating of the largest employees — is Cidara Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cidara Therapeutics, Inc. EBITDA is −40.46 M EUR, and current EBITDA margin is −38.13%. See more stats in Cidara Therapeutics, Inc. financial statements.
Like other stocks, A3D4A6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cidara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.